Objective To investigate whether a very early invasive strategy (IS)±revascularisation improves clinical outcomes compared with standard care IS in higher risk patients with non-ST-elevation acute ...

Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus ...

Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of TRINITY Trial of LuX-Valve Plus, a ...

Atrial fibrillation was the most common cardiovascular complication during ibrutinib therapy, occurring in 73 patients (13%), followed by new-onset heart failure (3.7%), cerebrovascular events (2.1%), ...

Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of TRINITY Trial of LuX-Valve Plus, a ...

4,17,18,20 Therefore, management of NASH deserves a holistic ... but we do not yet know if liver targeted treatment interventions will reduce them. NYHA=New York Heart Association. Small was defined ...